Literature DB >> 17702778

Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese.

Yih-Ru Wu1, Chiung-Mei Chen, Chih-Ying Chao, Long-Sun Ro, Rong-Kuo Lyu, Kuo-Hsuan Chang, Guey-Jen Lee-Chen.   

Abstract

BACKGROUND: Mutations in the glucocerebrosidase (GBA) gene have recently been identified as contributing to the development of Parkinson disease (PD) in Ashkenazi Jews.
METHODS: To investigate whether this finding can be confirmed in a Taiwanese population, we conducted a case control study in a cohort of 518 PD patients and 339 controls for the three common GBA mutations in Taiwan, L444P, RecNciI and R120W, using PCR restriction enzyme assay and DNA sequencing.
RESULTS: Heterozygous GBA mutations were detected in 16 PD patients (3.1%) and four controls (1.2%). Although this difference was not statistically significant (p = 0.0703), the average age at disease onset of the 16 PD patients (50.6 (12.3) years) was significantly younger than that of the total patient group (63.8 (10.5) years; p = 0.0007) and the non-carrier patient group (64.2 (10.2) years; p = 0.0005). After stratification by age, the frequency of mutation carriers was significantly higher for the early onset PD (EOPD, age at onset < or = 50 years) group than for age matched controls (12.9% vs 1.8%; p = 0.0335) and there was a trend towards an increased risk of the mutation carrier with EOPD (odds ratio 8.30; 95% CI 1.45 to 156.53). Clinically, all 16 patients carrying a GBA mutation presented with a typical parkinsonian phenotype and experienced a good or excellent response to levodopa.
CONCLUSIONS: Mutations of the GBA gene may be associated with the development of EOPD in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702778      PMCID: PMC2117856          DOI: 10.1136/jnnp.2006.105940

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

2.  Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.

Authors:  Robert Bussell; David Eliezer
Journal:  Biochemistry       Date:  2004-04-27       Impact factor: 3.162

Review 3.  Genetics of Parkinson's disease.

Authors:  Thomas Gasser
Journal:  Curr Opin Neurol       Date:  2005-08       Impact factor: 5.710

4.  The human glucocerebrosidase gene and pseudogene: structure and evolution.

Authors:  M Horowitz; S Wilder; Z Horowitz; O Reiner; T Gelbart; E Beutler
Journal:  Genomics       Date:  1989-01       Impact factor: 5.736

Review 5.  Genetic and environmental factors in the cause of Parkinson's disease.

Authors:  Thomas T Warner; Anthony H V Schapira
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

6.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.

Authors:  Judith Aharon-Peretz; Hanna Rosenbaum; Ruth Gershoni-Baruch
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

7.  The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  Neuropathol Appl Neurobiol       Date:  1989 Jan-Feb       Impact factor: 8.090

8.  Analysis of the glucocerebrosidase gene in Parkinson's disease.

Authors:  Christine Sato; Angharad Morgan; Anthony E Lang; Shabnam Salehi-Rad; Toshitaka Kawarai; Yan Meng; Peter N Ray; Lindsay A Farrer; Peter St George-Hyslop; Ekaterina Rogaeva
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

9.  Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations.

Authors:  Lei Wan; Chin-Moo Hsu; Chang-Hai Tsai; Cheng-Chun Lee; Wuh-Liang Hwu; Fuu-Jen Tsai
Journal:  Blood Cells Mol Dis       Date:  2006-03-20       Impact factor: 3.039

Review 10.  Gaucher's disease: a paradigm for interventional genetics.

Authors:  D P Germain
Journal:  Clin Genet       Date:  2004-02       Impact factor: 4.438

View more
  34 in total

Review 1.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

2.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

Review 3.  The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

Authors:  John DePaolo; Ozlem Goker-Alpan; Ted Samaddar; Grisel Lopez; Ellen Sidransky
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

4.  The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease.

Authors:  Usha Gutti; Hon-Chung Fung; Kathleen S Hruska; Mary E Lamarca; Chiung-Mei Chen; Yih-Ru Wu; Ellen Sidransky
Journal:  Arch Neurol       Date:  2008-06

Review 5.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

6.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

7.  The risk of Parkinson's disease in type 1 Gaucher disease.

Authors:  Gilberto Bultron; Katherine Kacena; Daniel Pearson; Michael Boxer; Ruhua Yang; Swati Sathe; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-02-23       Impact factor: 4.982

Review 8.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

9.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

10.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset.

Authors:  W C Nichols; N Pankratz; D K Marek; M W Pauciulo; V E Elsaesser; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.